The current clinical pipeline for new antibiotics fails to address the significant threat posed by drug-resistant Gram-negative bacteria which have been identified by the World Health Organization (WHO) as a global health priority. As companies continue to leave the field of antibiotic development, many researchers have also retired or re-focused their activities on other areas. The shifts away from the field risk the loss of invaluable experience and knowledge that is crucial for the discovery, research and development of urgently needed antimicrobial treatments.

The Global Antibiotic R&D Partnership (GARDP) launched REVIVE in 2018 to ensure knowledge is retained, and the antimicrobial R&D community is supported online to connect, share, and acquire information. Through our external scientific affairs & REVIVE activities, we are helping advance the development of new treatments by freely sharing the knowledge and skills of antimicrobial R&D experts with the global research community.

REQUIRE DRUG DEVELOPERS

REVIVE provides all those in the antimicrobial field, from academia, start-ups, biotech and large companies, with access to scientific advice from experienced drug developers. The REVIVE expert network of over 90 specialists from 15 countries is continuously growing with the aim of representing an international group of senior scientific and medical professionals.

SHARING KNOWLEDGE

The launch of a new Antimicrobial R&D Encyclopaedia, as part of a broader resource section, is planned for summer 2020 and will define many terms used in the field, with some featured in videos by leading experts.
**3 THREE AIMS OF REVIVE**

**FACILITATE LEARNING**
**CONNECT PEOPLE**
**KNOWLEDGE SHARING**

**5 BY 25**
GARDP is calling on the world to support the delivery of five new treatments by 2025 to tackle the drug-resistant infections that pose the greatest threat to global health and economic security. We are seeking €500 million to develop these treatments and ensure their responsible use and sustainable access.

GARDP’s external scientific affairs & REVIVE activities are helping us achieve 5 BY 25. By facilitating learning, connecting the antimicrobial R&D community across sectors, and ensuring that valuable expert knowledge is shared globally, this platform is helping to accelerate the research and development of new life-saving antibiotics.

**A GLOBAL PARTNERSHIP**
REVIVE has partnered with leading experts from across the world to share their critical knowledge and experience with users.

There are currently over 90 world-class experts from 15 countries on the platform:

- Australia
- Austria
- Belgium
- Canada
- France
- Germany
- India
- Luxembourg
- Netherlands
- South Africa
- Spain
- Sweden
- Switzerland
- UK
- USA